Focus: ADC Therapeutics is a oncology-focused biotech specializing in antibody-drug conjugates (ADCs) for hematologic and solid tumors. The company is private, founded in 2020, and headquartered in New Providence, NJ.
Profile data last refreshed 7h ago · AI intelligence enriched 2w ago
Cooling — net -8 jobs in 30d
2 added, 10 removed. Slower than typical.
ADC Therapeutics offers specialized deep-tech oncology expertise but is in acute distress post-safety event; suitable only for risk-tolerant professionals seeking early-stage biotech intensity and potential upside from pipeline catalysts.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Sole approved ADC generating commercial revenue; recent safety signal (27 patient deaths) has triggered FDA strategy review and 17% workforce reduction.
Help build intelligence for ADC Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from ADC Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
ADC Therapeutics SA|Price:1.150|Chg%:-0.045 - TradingKey
ADC Therapeutics SA|Price:1.150|Chg%:-0.045 TradingKey
ADC Therapeutics stock stabilizes as Zynlonta revenue supports biotech valuation - Ad-hoc-news.de
ADC Therapeutics stock stabilizes as Zynlonta revenue supports biotech valuation Ad-hoc-news.de
ADC Therapeutics stock trades steady as revenue grows and liquidity plan develops - Ad-hoc-news.de
ADC Therapeutics stock trades steady as revenue grows and liquidity plan develops Ad-hoc-news.de
ADC Therapeutics updates trial strategy, shares react to oncology shift - AD HOC NEWS
ADC Therapeutics updates trial strategy, shares react to oncology shift AD HOC NEWS
Layoff Tracker: CLINUVEL will cut up to 20% of staff, relocate HQ to New York - BioSpace
Layoff Tracker: CLINUVEL will cut up to 20% of staff, relocate HQ to New York BioSpace
ADC Therapeutics cuts jobs as Zynlonta FDA talks loom - The Pharma Letter
ADC Therapeutics cuts jobs as Zynlonta FDA talks loom The Pharma Letter
Showing 6 of 10 news items
Based on last 4 crawl cycles
Acute distress signal: recent mass layoff tied to safety event in approved product signals restructuring, potential regulatory setback, and high execution risk.
Recent peer-reviewed publications with author affiliations at this company
+1 more
+2 more
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo